<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Amiodarone and thyroid dysfunction
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Amiodarone and thyroid dysfunction
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Amiodarone and thyroid dysfunction
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Douglas S Ross, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David S Cooper, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jean E Mulder, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 25, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         , a class III antiarrhythmic drug, has multiple effects on myocardial depolarization and repolarization that make it an extremely effective antiarrhythmic drug. However, amiodarone is associated with a number of side effects, including thyroid dysfunction (both hypo- and hyperthyroidism), which is due to amiodarone's high iodine content and its direct toxic effect on the thyroid. This topic will review the major effects of amiodarone on thyroid function. The clinical use and other side effects of amiodarone are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/926.html" rel="external">
          "Amiodarone: Clinical uses"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/931.html" rel="external">
          "Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PHARMACOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         contains two iodine atoms. It is estimated that amiodarone metabolism in the liver releases approximately 3 mg of inorganic iodine into the systemic circulation per 100 mg of amiodarone ingested. The average iodine content in a typical American diet is approximately 0.3 mg/day. Thus, 6 mg of iodine associated with a 200 mg dose of amiodarone markedly increases the daily iodine load [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         is very lipophilic and is concentrated in adipose tissue, cardiac and skeletal muscle, and the thyroid. Elimination from the body occurs with a half-life of approximately 100 days [
         <a href="#rid3">
          3
         </a>
         ]. Amiodarone toxicity can therefore occur well after drug withdrawal [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         The effects of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         on thyroid function can be divided into those effects that are intrinsic properties of the drug and those effects that are due to iodine.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Intrinsic drug effects
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         inhibits outer ring 5'-monodeiodination of thyroxine (T4), thus decreasing triiodothyronine (T3) production; reverse T3 accumulates since it is not metabolized to T2 [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         (and particularly the metabolite desethylamiodarone) blocks T3-receptor binding to nuclear receptors [
         <a href="#rid6">
          6
         </a>
         ] and decreases expression of some thyroid hormone-related genes [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         may have a direct toxic effect on thyroid follicular cells, which results in a destructive thyroiditis [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="local">
          'Type II'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Effects due to iodine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Iodine is a substrate for thyroid hormone synthesis. It is actively transported into thyroid follicular cells and organified onto tyrosyl residues in thyroglobulin.
        </p>
        <p>
         The normal autoregulation of iodine prevents normal individuals from becoming hyperthyroid after exposure to an iodine load (eg, radiocontrast). When intrathyroidal iodine concentrations reach a critical high level, iodine transport and thyroid hormone synthesis are transiently inhibited until intrathyroidal iodine stores return to normal levels (the Wolff-Chaikoff effect). (See
         <a class="medical medical_review" href="/z/d/html/7837.html" rel="external">
          "Thyroid hormone synthesis and physiology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7844.html" rel="external">
          "Iodine-induced thyroid dysfunction"
         </a>
         .)
        </p>
        <p>
         Patients with underlying thyroid disease, however, have defects in autoregulation of iodine:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with autoimmune thyroid disease "fail to escape" from the Wolff-Chaikoff effect. The result is the development of goiter and hypothyroidism in Hashimoto's disease [
         <a href="#rid9">
          9
         </a>
         ] and amelioration of Graves' hyperthyroidism.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with areas of autonomous function within a nodular goiter do not autoregulate iodine and the addition of more substrate may result in excessive thyroid hormone synthesis and thyrotoxicosis (Jod-Basedow) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          RISK OF THYROID DYSFUNCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both hypo- and hyperthyroidism are complications of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         therapy [
         <a href="#rid1">
          1,11-14
         </a>
         ]. In a meta-analysis of four randomized trials involving 1465 euthyroid patients, the prevalence of clinical thyroid disease was higher in patients receiving amiodarone therapy (150 to 330 mg/day for a minimum of one year) when compared with placebo (3.7 versus 0.4 percent, respectively) [
         <a href="#rid13">
          13
         </a>
         ]. In other reviews and reports, the risk of amiodarone-induced thyroid dysfunction ranges from 2 to 30 percent, depending upon an individual's underlying thyroid status, dietary iodine intake, and whether cases of subclinical thyroid disorders (eg, slight rise in thyroid-stimulating hormone [TSH] without symptoms) are included [
         <a href="#rid1">
          1,11,12,14-17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Underlying thyroid function
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical effects of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         on thyroid function in any individual are dependent upon the underlying status of that individual's thyroid gland.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Normal
         </span>
         <span class="headingEndMark">
          —
         </span>
         In normal, euthyroid individuals receiving
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , acute changes in thyroid function tests include [
         <a href="#rid1">
          1,18
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum T4 and free T4 concentrations rise by 20 to 40 percent during the first month of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum T3 concentrations decrease by up to 30 percent within the first few weeks of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum reverse T3 concentrations increase by 20 percent soon after the initiation of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The serum TSH concentration usually rises slightly after the initiation of treatment and may exceed the upper limit of normal.
        </p>
        <p>
        </p>
        <p>
         After three to six months of therapy, a steady state is reached in most patients who were euthyroid at baseline:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum TSH concentration normalizes
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum total T4, free T4 and reverse T3 concentrations remain slightly elevated or in the upper normal range
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum T3 concentrations remain in the low normal range
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         may also cause a destructive thyroiditis in patients without underlying thyroid disease [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="local">
          'Type II'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Abnormal
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with underlying autoimmune thyroid disease are more likely to develop amiodarone-induced hypothyroidism, presumably due to failure to escape from the Wolff-Chaikoff effect. (See
         <a class="local">
          'Effects due to iodine'
         </a>
         above and
         <a class="local">
          'Hypothyroidism'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with underlying multinodular goiter or latent Graves' disease, hyperthyroidism (increased synthesis of T4 and T3) may occur. The excess iodine from the
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         provides increased substrate, resulting in enhanced thyroid hormone production [
         <a href="#rid19">
          19
         </a>
         ]. (See
         <a class="local">
          'Type I'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Dietary iodine intake
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dietary iodine intake also affects an individual's risk of amiodarone-induced thyroid dysfunction:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In iodine-sufficient areas, amiodarone-induced hypothyroidism appears to be more common than hyperthyroidism [
         <a href="#rid15">
          15,20-22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In contrast, amiodarone-induced hyperthyroidism is more common than hypothyroidism in iodine-deficient regions [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         One study illustrates the importance of both the underlying thyroid status and dietary iodine intake in relation to the risk of developing amiodarone-induced thyroid dysfunction. In Worcester, Massachusetts, an area with iodine sufficiency and a high prevalence of autoimmune thyroid disease,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         was associated with a 22 percent rate of hypothyroidism and a 2 percent rate of hyperthyroidism [
         <a href="#rid15">
          15
         </a>
         ]. In contrast, in Pisa, Italy, an area of borderline iodine intake and a high prevalence of nodular goiter, amiodarone was associated with a 5 percent rate of hypothyroidism and a 9.6 percent rate of hyperthyroidism.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          HYPOTHYROIDISM
         </span>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Epidemiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         As noted above, transient changes in thyroid function tests often occur in euthyroid individuals treated with
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         . However, most patients remain euthyroid during amiodarone therapy (89 percent in one study) [
         <a href="#rid23">
          23
         </a>
         ]. In one trial, overt hypothyroidism (TSH &gt;10 mU/L) developed in 5 percent of patients receiving amiodarone, but subclinical hypothyroidism (TSH 4.5 to 10 mU/L) developed in an additional 25 percent [
         <a href="#rid14">
          14
         </a>
         ]. In a meta-analysis, 14 percent of patients receiving amiodarone became hypothyroid [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Patients with underlying Hashimoto's thyroiditis or positive antithyroid antibodies are more likely to develop persistent hypothyroidism [
         <a href="#rid4">
          4,25
         </a>
         ]. This observation may explain the higher prevalence of amiodarone-induced hypothyroidism in women compared with men [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         In iodine-sufficient areas, amiodarone-induced hypothyroidism is more common than hyperthyroidism [
         <a href="#rid15">
          15,20-22
         </a>
         ] and may occur in up to 20 percent of patients treated with
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         [
         <a href="#rid11">
          11
         </a>
         ]. In contrast, amiodarone-induced hyperthyroidism is more common than hypothyroidism in iodine-deficient regions [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="local">
          'Dietary iodine intake'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transient hypothyroidism may occur in the infants of women treated with
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         during pregnancy. As an example, in a study of 64 pregnancies in which amiodarone was given to the mother, 11 infants (17 percent) had transient hypothyroidism; 2 of the 11 had a goiter [
         <a href="#rid26">
          26
         </a>
         ]. Hypothyroidism was transient in all cases, and only five infants were treated short term with thyroid hormones.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Clinical manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical manifestations and diagnosis of amiodarone-associated hypothyroidism are similar to those of hypothyroidism from any cause. Hypothyroidism and hypothyroid symptoms may develop as soon as two weeks or as late as 39 months after the initiation of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         therapy [
         <a href="#rid27">
          27,28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7846.html" rel="external">
          "Clinical manifestations of hypothyroidism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients should have thyroid function assessed several weeks after starting
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         and every few months thereafter for the development of overt hypothyroidism, especially those with evidence for autoimmunity prior to initiating amiodarone [
         <a href="#rid9">
          9,25
         </a>
         ]. Hypothyroidism should be diagnosed on the basis of a screening serum TSH value before the patient has symptoms. Since small increases in serum TSH concentrations (10 to 20 mU/L) are seen in euthyroid patients for the first three to six months after amiodarone therapy is initiated, amiodarone-induced hypothyroidism should only be diagnosed when serum T4 concentrations are low-normal or low, or mild TSH elevation persists. (See
         <a class="medical medical_review" href="/z/d/html/7893.html" rel="external">
          "Diagnosis of and screening for hypothyroidism in nonpregnant adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thyroid function can be easily normalized by replacement with T4 (
         <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">
          levothyroxine
         </a>
         ) while
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         is continued. The goal of therapy is to restore the serum TSH concentration to normal, keeping in mind that a larger than usual dose may be required because of the likely effects of amiodarone on intrapituitary T4 metabolism and T3 production and, possibly, thyroid hormone action [
         <a href="#rid11">
          11
         </a>
         ]. The patient should be retested if amiodarone is withdrawn at a later date. (See
         <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">
          "Treatment of primary hypothyroidism in adults"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         is usually
         <strong>
          not
         </strong>
         discontinued, unless it fails to control the underlying arrhythmia. However, if amiodarone is stopped, hypothyroidism in patients with no apparent preexisting thyroid disease often resolves. In contrast, hypothyroidism may persist after withdrawal of amiodarone in patients who have underlying chronic autoimmune thyroiditis with high titers of antithyroid peroxidase (TPO) antibodies and goiter, and they therefore require permanent T4 therapy [
         <a href="#rid1">
          1,4,11,12,25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          HYPERTHYROIDISM
         </span>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Types of hyperthyroidism
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are two types of amiodarone-induced thyrotoxicosis (AIT). In type I, there is increased synthesis of thyroid hormone, whereas in type II, there is excess release of T4 and T3 due to a destructive thyroiditis. These types differ in their pathogenesis, management, and outcome [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Type I
         </span>
         <span class="headingEndMark">
          —
         </span>
         In type I AIT, there is hyperthyroidism with increased synthesis of T4 and T3. This type is typically seen in patients with preexisting multinodular goiter or latent Graves' disease; the excess iodine from
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         provides increased substrate, resulting in enhanced thyroid hormone production [
         <a href="#rid19">
          19
         </a>
         ]. While most of these patients have underlying multinodular goiter, occasional patients have latent Graves' disease that becomes overt upon exposure to large amounts of iodine [
         <a href="#rid30">
          30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7844.html" rel="external">
          "Iodine-induced thyroid dysfunction"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h3">
          Type II
         </span>
         <span class="headingEndMark">
          —
         </span>
         In type II AIT, the hyperthyroidism is a destructive thyroiditis that results in excess release of T4 and T3, without increased hormone synthesis. It typically occurs in patients without underlying thyroid disease and is caused by a direct toxic effect of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         on thyroid follicular epithelial cells [
         <a href="#rid31">
          31-33
         </a>
         ].
        </p>
        <p>
         The hyperthyroid phase may last from several weeks to several months, and it is often followed by a hypothyroid phase with eventual recovery in most, but not all, patients. For unclear reasons, the toxic effects of the drug may take two to three years to become manifest. (See
         <a class="medical medical_review" href="/z/d/html/7824.html" rel="external">
          "Overview of thyroiditis"
         </a>
         .)
        </p>
        <p>
         In many cases, mixed forms of AIT exist, making both diagnosis and treatment challenging (see
         <a class="local">
          'Diagnosis'
         </a>
         above and
         <a class="local">
          'Treatment'
         </a>
         above). The risk of either type increases with higher cumulative doses [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Prevalence
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of AIT, as well as the distribution by type (I or II), varies by geographical region. This is thought to be primarily due to differences in dietary iodine intake (see
         <a class="local">
          'Dietary iodine intake'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the United States, 3 to 5 percent of patients treated with
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         become hyperthyroid, usually between four months and three years after the initiation of the drug [
         <a href="#rid14">
          14,25
         </a>
         ]. The majority of cases are type II.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In iodine-deficient regions, AIT is more common than in the United States, occurring in approximately 10 to 12 percent of patients with type I AIT usually predominating [
         <a href="#rid11">
          11,12,15
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         However, the distribution of cases by type may be changing, as illustrated in a report of 215 consecutive patients with AIT seen at a single institution in Italy over 26 years [
         <a href="#rid35">
          35
         </a>
         ]. In 1980 compared with 2006, 2 of 6 (40 percent) versus 12 of 14 (86 percent) of new AIT cases were type II. Possible explanations for this observation include improved dietary iodine intake in the region and the avoidance of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         in patients with known thyroid disease.
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Clinical manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical manifestations of amiodarone-induced hyperthyroidism are often masked because its beta-blocking activity minimizes many of the adrenergic manifestations of thyroid hormone excess and possibly because
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         metabolites may block binding of T3 to its nuclear receptor [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Common presenting symptoms and signs include the development or redevelopment of atrial arrhythmias; exacerbation of ischemic heart disease or heart failure; or unexplained weight loss, restlessness, or low-grade fever [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Patients with amiodarone-induced hyperthyroidism have a threefold higher rate of major adverse cardiovascular events (mostly ventricular arrhythmias) compared with euthyroid controls [
         <a href="#rid36">
          36
         </a>
         ]. The presence of severe left ventricular dysfunction in patients with amiodarone-induced hyperthyroidism (type I or type II) may be associated with increased mortality [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Differentiating the two types
         </span>
         <span class="headingEndMark">
          —
         </span>
         The distinction between type I and type II is critical since therapy differs for the two types. However, the distinction may be difficult using clinical criteria, partly because some patients may have a mixture of both mechanisms [
         <a href="#rid33">
          33
         </a>
         ]. Thyroid function tests are not helpful for differentiating type I from type II hyperthyroidism.
        </p>
        <p>
         Type I, when seen in the setting of an underlying autonomous nodule or goiter, tends to occur early after
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         treatment is started (at a median 3.5 months in one study), while type II occurs much later (median 30 months) [
         <a href="#rid38">
          38
         </a>
         ]. When thyrotoxicosis initially occurs after amiodarone has been discontinued (19 percent of AIT in this study), it is much more likely to be type II (95 percent in this study) [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         In patients not taking
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , the radioiodine uptake is the primary test used to distinguish between destructive subacute thyroiditis and hyperthyroidism associated with de novo synthesis of thyroid hormone; the 24-hour radioiodine uptake is &lt;1 percent in subacute thyroiditis and elevated or normal in toxic nodular goiter or Graves' disease.
        </p>
        <p>
         However, the daily ingestion of 6 mg or more of bioavailable iodine with
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         results in sufficiently high serum levels of iodine that compete with the tracer used to perform the uptake test. Therefore, the majority of patients with type I (as well as all patients with type II) has uptakes that are less than 1 percent [
         <a href="#rid39">
          39
         </a>
         ]. In one European study, a significant percentage of patients with type I hyperthyroidism had measurable or even elevated uptakes [
         <a href="#rid40">
          40
         </a>
         ]; however, this is an unusual finding in the United States. (See
         <a class="medical medical_review" href="/z/d/html/7871.html" rel="external">
          "Disorders that cause hyperthyroidism"
         </a>
         .)
        </p>
        <p>
         The criteria used to attempt to distinguish type I from type II hyperthyroidism are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the 24-hour radioiodine uptake is detectable, it suggests type I AIT [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with type I often have multinodular goiters or diffuse goiter, whereas those with type II usually have no goiter or a small diffuse goiter.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In two studies, serum thyroglobulin concentrations were higher and serum interleukin-6 concentrations were lower in patients with type I hyperthyroidism [
         <a href="#rid29">
          29,32
         </a>
         ]. In a third study, interleukin-6 concentrations were not useful for distinguishing type I from type II [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two studies reported that color-flow Doppler sonography (CFDS) may distinguish type I (increased vascularity) from type II (absent vascularity) hyperthyroidism [
         <a href="#rid41">
          41,42
         </a>
         ]; 80 percent of patients could be classified by CFDS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, interpretations of CFDS in amiodarone-associated hyperthyroidism require an experienced sonographer. It is straightforward to separate patients into those with increased and low flow when a group of patients with amiodarone-associated hyperthyroidism are being scanned sequentially, but due to the lack of an accepted "gold standard," it may be difficult to interpret the CFDS of a single thyroid gland scanned during a typical day of multiorgan ultrasound examinations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two reports utilized technetium-99m (99mTc)-sestamibi thyroid uptake and scintigraphy to distinguish type I (normal or increased) from type II (decreased) and found this to be more useful than CFDS [
         <a href="#rid43">
          43,44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of thyrotropin receptor antibodies (TRAb) suggests Graves' disease. However, in patients suspected of having type I AIT, TRAb measurements to diagnose Graves' disease should be measured using a thyroid-stimulating immunoglobin (TSI) assay, if available, and not a thyrotropin-binding inhibitory immunoassay (TBII) assay. TBII assays cannot distinguish between type I and II AIT.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As an example, in one study, 21 of 309 patients (7 percent) had positive TRAb when measured in a TBII [
         <a href="#rid45">
          45
         </a>
         ]. Of these, 43 percent appeared to have type I AIT based on color-flow Doppler or response to
         <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">
          methimazole
         </a>
         , while 57 percent appeared to have type II AIT based on response to corticosteroids. TRAb, measured by a TSI assay, was positive in patients suspected of having type I AIT and negative in those suspected of having type II AIT.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Treatment
         </span>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h3">
          Should amiodarone be discontinued?
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are few data that directly address this question. In a retrospective study from Italy of type II AIT, the median time to normalize thyroid function was similar whether
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         was continued (n = 8) or discontinued (n = 32) [
         <a href="#rid46">
          46
         </a>
         ]. However, five of seven patients taking amiodarone had recurrent thyrotoxicosis compared with 3 of 32 patients in whom the amiodarone was discontinued. In a study from the Netherlands of type II AIT in which 36 patients were treated with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , sodium perchlorate, or both, therapy was effective in all patients receiving prednisone or perchlorate plus prednisone, despite continuation of amiodarone in all patients [
         <a href="#rid47">
          47
         </a>
         ]. Recurrent thyrotoxicosis occurred in only three patients (8 percent).
        </p>
        <p>
         When deciding whether to discontinue
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , the following should be considered:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         may be necessary to control a life-threatening arrhythmia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Since the half-life of elimination from the body is approximately 100 days, there is no immediate benefit to stopping
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         appears to ameliorate hyperthyroidism by blocking T4 to T3 conversion, beta-adrenergic receptors, and possibly T3 receptors. Stopping amiodarone might actually exacerbate hyperthyroid symptoms and signs.
        </p>
        <p>
        </p>
        <p>
         In patients who develop AIT in whom the
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         was prescribed for life-threatening ventricular arrhythmias (and is effective), we suggest continuing the amiodarone and simultaneously treating the hyperthyroidism. If the amiodarone was not prescribed for life-threatening ventricular arrhythmias (or is ineffective), we suggest discontinuing the drug in consultation with the patient's cardiologist if alternative antiarrhythmics can be used. For type I AIT, amiodarone should not be discontinued until hyperthyroid symptoms are well controlled with thionamides, since worsening hyperthyroid symptoms due to increased T3 levels may occur when the amiodarone is discontinued.
        </p>
        <p class="headingAnchor" id="H756510">
         <span class="h3">
          Treatment of type I AIT
         </span>
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h4">
          Thionamides
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with type I hyperthyroidism usually respond to a thionamide drug, although the response may be slow and large doses may be required, presumably because of very high intrathyroidal iodine stores [
         <a href="#rid4">
          4,49
         </a>
         ]. The average initial dose is often 30 to 40 mg of
         <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">
          methimazole
         </a>
         daily, with careful monitoring for adverse effects such as skin rash, arthralgia, hepatotoxicity, and, rarely, bone marrow suppression. The risk of agranulocytosis in one study was higher in patients with amiodarone-induced thyrotoxicosis (8 of 593 [1.35 percent]), compared with patients with thyrotoxicosis unrelated to
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         (20 of 14,188 [0.14 percent]) [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7876.html" rel="external">
          "Thionamides in the treatment of Graves' disease", section on 'Initiation of therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7875.html" rel="external">
          "Thionamides: Side effects and toxicities", section on 'Agranulocytosis'
         </a>
         .)
        </p>
        <p>
         The addition of perchlorate, which blocks further iodine uptake by the thyroid, may be of benefit [
         <a href="#rid51">
          51
         </a>
         ], but chronic use has been associated (rarely) with aplastic anemia, and perchlorate is not currently available in the United States. The addition of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         carbonate to the antithyroid drug has also been reported to speed recovery when the hyperthyroidism is severe [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         Thionamides are usually tapered to a low maintenance dose in patients with hyperthyroidism. In amiodarone-associated type I hyperthyroidism, care must be taken not to reduce the dose of thionamide too quickly, or patients might develop recurrent and prolonged hyperthyroidism. An alternative strategy is to continue high-dose thionamides and add T4 after patients become hypothyroid.
        </p>
        <p>
         If
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         is stopped (eg, if there is evidence of toxicity in other organs or if it is ineffective as an antiarrhythmic), depending upon the clinical setting one might add beta-adrenergic blocking drugs and iopanoic acid to block T4 to T3 conversion. However, neither iopanoic acid nor ipodate are available in the United States. It is unclear when, or even whether, they will ever again be marketed in the United States. (See
         <a class="medical medical_review" href="/z/d/html/7877.html" rel="external">
          "Iodinated radiocontrast agents in the treatment of hyperthyroidism"
         </a>
         .)
        </p>
        <p>
         Patients with iodine-induced hyperthyroidism who are continuing
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         will need to continue thionamides. If amiodarone is subsequently discontinued, the thionamide should be continued until measurement of urine iodine returns to normal. This may take 6 to 18 months, after which one could cautiously attempt to taper antithyroid therapy. In one study, when amiodarone was reintroduced in patients with a history of AIT type I who were not taking a thionamide, 8 of 11 patients (73 percent) developed recurrent AIT [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h4">
          Radioiodine
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the radioiodine uptake is high enough, one could treat the patient with radioiodine. In one series of 14 patients in whom
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         had been discontinued due to hyperthyroidism, subsequent radioiodine ablation of the thyroid allowed reintroduction of amiodarone (and control of recurrent tachyarrhythmias) in 12 of the 14 subjects [
         <a href="#rid54">
          54
         </a>
         ]. However, radioiodine ablation is usually not an option due to low radioiodine uptake in these patients.
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h4">
          Surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who are refractory to antithyroid drug therapy should be treated by thyroidectomy. This recommendation is consistent with the European Thyroid Association guidelines for the management of amiodarone-associated thyroid dysfunction [
         <a href="#rid55">
          55
         </a>
         ]. When balancing the risk of a surgical procedure during careful cardiovascular monitoring with the risk of several months of unmonitored and uncontrolled thyrotoxicosis, the advantages of surgery in this setting become compelling [
         <a href="#rid56">
          56-58
         </a>
         ]. In one study of 207 patients, 51 of whom had surgery and 156 of whom were treated medically, overall and cardiovascular mortality was lower in the surgery group due to reduced mortality among patients with moderate to severe reductions in left ventricular ejection fraction (under 40 percent) [
         <a href="#rid59">
          59
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7880.html" rel="external">
          "Surgical management of hyperthyroidism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h3">
          Treatment of type II AIT
         </span>
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h4">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with type II hyperthyroidism respond well to moderately large doses of corticosteroids (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         40 to 60 mg/day) [
         <a href="#rid29">
          29,60
         </a>
         ], even if the
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         is continued [
         <a href="#rid39">
          39,61
         </a>
         ]. We typically start with prednisone (40 to 60 mg/day) and continue therapy for one to three months before tapering (to avoid exacerbations of hyperthyroidism). Some improvement is usually seen as early as one week [
         <a href="#rid29">
          29
         </a>
         ]. In one study of 66 patients, 60 percent were euthyroid within one month and 16 percent remained hyperthyroid for more than three months [
         <a href="#rid62">
          62
         </a>
         ]. Prolonged hyperthyroidism was associated with higher serum free T4 levels and goiter.
        </p>
        <p>
         Glucocorticoid therapy is more effective than iopanoic acid. In a prospective, randomized trial, both glucocorticoids and iopanoic acid were effective in type II hyperthyroidism, but thyroid function returned to normal more rapidly after steroid administration [
         <a href="#rid63">
          63
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7877.html" rel="external">
          "Iodinated radiocontrast agents in the treatment of hyperthyroidism"
         </a>
         .)
        </p>
        <p>
         In a randomized, clinical trial, the addition of perchlorate to
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         added no benefit [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Patients with type II AIT may develop transient (or sometimes permanent) hypothyroidism when the hyperthyroidism resolves [
         <a href="#rid8">
          8
         </a>
         ] and benefit from T4 replacement. (See
         <a class="medical medical_review" href="/z/d/html/7824.html" rel="external">
          "Overview of thyroiditis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4085550681">
         <span class="h4">
          Surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who are refractory to glucocorticoids should be treated with thyroidectomy. In the study of 207 patients with AIT described above, 64 percent of patients who had surgery for amiodarone-induced thyrotoxicosis had type II AIT [
         <a href="#rid59">
          59
         </a>
         ]. (See
         <a class="local">
          'Surgery'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h3">
          Treatment if mechanism unknown
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients may have a "mixed" form of thyrotoxicosis or the underlying cause (type I or type II) may be uncertain. In such cases, a combination of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (40 mg/day) and
         <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">
          methimazole
         </a>
         (40 mg/day) is prudent initial therapy. A rapid response suggests type II hyperthyroidism; the methimazole can then be tapered or stopped and, if indicated, iopanoic acid can be added (if available). A poor response initially argues for type I hyperthyroidism. If so, steroids can be tapered and, depending upon the subsequent course, perchlorate,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , and/or surgery may be necessary.
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since thyroid dysfunction is relatively common with
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         therapy, all patients should have thyroid function tests checked before starting therapy and at three- to four-month intervals during treatment [
         <a href="#rid12">
          12
         </a>
         ]. Thyroid dysfunction may occur after amiodarone withdrawal, and therefore, thyroid function should be assessed for at least one year after the drug is discontinued, and longer in patients with high cumulative doses or a history of hypothyroidism during treatment. In a study of 71 patients followed after stopping amiodarone, five (7 percent) developed type II amiodarone-induced thyrotoxicosis (AIT) between 7 and 16 months after withdrawal [
         <a href="#rid64">
          64
         </a>
         ]. Compared with patients who did not develop AIT, they had been on amiodarone longer (mean 76 versus 16 months) and had been more likely to have had hypothyroidism during amiodarone therapy.
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h1">
          PATIENTS ON WARFARIN
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients taking
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         who are also being treated with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , the consequences of amiodarone-induced thyroid dysfunction include a significant influence on warfarin response. The effect of warfarin is potentiated by thyrotoxicosis and attenuated in hypothyroidism [
         <a href="#rid65">
          65
         </a>
         ]. In addition, amiodarone itself has effects on warfarin pharmacokinetics, which may be important if the amiodarone is discontinued because of thyroid dysfunction. In any patient with amiodarone-induced thyroid dysfunction who is also taking warfarin, the International Normalized Ratio (INR) should be monitored closely and appropriate adjustments in warfarin dosing made. (See
         <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">
          "Warfarin and other VKAs: Dosing and adverse effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1552887585">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109107.html" rel="external">
          "Society guideline links: Hyperthyroidism"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/109155.html" rel="external">
          "Society guideline links: Hypothyroidism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H33">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thyroid dysfunction (both hypo- and hyperthyroidism) is a common complication of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         therapy due to direct effects of the drug on the thyroid, as well as its high iodine content. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Direct effects of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         on the thyroid include: inhibition of outer ring 5'-monodeiodination of thyroxine (T4), thus decreasing triiodothyronine (T3) production; blocking T3-receptor binding to nuclear receptors; decreased expression of some thyroid hormone-related genes; and a direct toxic effect on the thyroid (destructive thyroiditis). (See
         <a class="local">
          'Intrinsic drug effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other effects on the thyroid are due to the extremely high iodine content of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         . (See
         <a class="local">
          'Effects due to iodine'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transient changes in thyroid function tests often occur in euthyroid individuals treated with
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         . While most patients remain euthyroid during amiodarone therapy, the clinical effects of amiodarone on thyroid function in any individual are dependent upon underlying thyroid status and dietary iodine intake:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with underlying autoimmune thyroid disease are at highest risk for amiodarone-induced hypothyroidism (due to failure to escape from the Wolff-Chaikoff effect). (See
         <a class="local">
          'Abnormal'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with nodular goiter are at increased risk of type I amiodarone-induced thyrotoxicosis (AIT). The excess iodine from the
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         provides increased substrate, resulting in enhanced thyroid hormone synthesis and hyperthyroidism. (See
         <a class="local">
          'Type I'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Destructive thyroiditis (type II AIT) typically occurs in patients with no underlying thyroid disease. (See
         <a class="local">
          'Type II'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In iodine-sufficient areas, amiodarone-induced hypothyroidism appears to be more common than hyperthyroidism. In contrast, amiodarone-induced hyperthyroidism (usually type I AIT) is more common than hypothyroidism in iodine-deficient regions. (See
         <a class="local">
          'Dietary iodine intake'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We suggest continuing
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         therapy in patients who develop amiodarone-induced hypothyroidism (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The diagnosis and treatment of amiodarone-induced hypothyroidism is the same as for other patients with primary hypothyroidism. Euthyroidism should be restored by replacement with thyroid hormone. Thyroid hormone, in doses larger than normal, is often required. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         should only be discontinued if it fails to control the underlying arrhythmia. If amiodarone is discontinued in a patient without preexisting autoimmune thyroid disease, the hypothyroidism often resolves. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There are two types of AIT. In type I, there is increased synthesis of thyroid hormone (excess iodine provides the increased substrate), whereas in type II, there is excess release of T4 and T3 due to a destructive thyroiditis (direct toxic effect of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         on the thyroid gland). For patients with type II AIT, the hyperthyroid phase may last from several weeks to several months and is often followed by a hypothyroid phase and then recovery. (See
         <a class="local">
          'Types of hyperthyroidism'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         It is often difficult to distinguish between the two types, and some patients may have elements of both. The 24-hour radioiodine uptake is typically
         <strong>
          not
         </strong>
         able to distinguish between types I and II AIT, because the high levels of ingested iodine with
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         results in 24-hour uptakes of less than 1 percent in most patients with either type I or type II AIT. Technetium-99m (99mTc)-sestamibi imaging, where available, or color-flow Doppler sonography (CFDS) may be the best ways of distinguishing between the two types of AIT. (See
         <a class="local">
          'Differentiating the two types'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who develop AIT in whom the
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         was prescribed for life-threatening ventricular arrhythmias (and is effective), we suggest continuing the amiodarone and simultaneously treating the hyperthyroidism (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Should amiodarone be discontinued?'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who develop AIT in whom the
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         was not prescribed for life-threatening ventricular arrhythmias (or is ineffective), we suggest discontinuing the drug (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). This should only be done in consultation with the patient's cardiologist if alternative antiarrhythmics can be used. For type I AIT, amiodarone should not be discontinued until hyperthyroid symptoms are well controlled with thionamides, since worsening hyperthyroid symptoms due to increased T3 levels may occur when the amiodarone is discontinued. (See
         <a class="local">
          'Should amiodarone be discontinued?'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For the treatment of
         <strong>
          type I AIT,
         </strong>
         we suggest thionamides as our first choice of therapy (whether
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         is continued or discontinued) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ) (see
         <a class="local">
          'Thionamides'
         </a>
         above). Although radioiodine ablation has been reported to have been used (in rare patients with high enough radioiodine uptake), this is usually not an option due to low radioiodine uptake in the majority of type I patients. (See
         <a class="local">
          'Radioiodine'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Higher than average initial doses of thionamides are usually needed (30 to 40 mg of
         <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">
          methimazole
         </a>
         or 450 to 600 mg
         <a class="drug drug_general" data-topicid="9830" href="/z/d/drug information/9830.html" rel="external">
          propylthiouracil
         </a>
         [PTU] daily). Perchlorate or
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         are sometimes added to speed recovery, however, perchlorate is not available in the United States. In addition, perchlorate has been associated, albeit rarely, with aplastic anemia. (See
         <a class="local">
          'Thionamides'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For the treatment of
         <strong>
          type II AIT
         </strong>
         , we suggest glucocorticoid therapy as our first-line drug (whether
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         is continued or discontinued) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). We typically start with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (40 to 60 mg/day) and continue therapy for one to two months before tapering (to avoid exacerbations of hyperthyroidism). (See
         <a class="local">
          'Glucocorticoids'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with type I or type II AIT who are refractory to medical therapy should be treated by thyroidectomy. When balancing the risk of a surgical procedure during careful cardiovascular monitoring with the risk of several months of unmonitored and uncontrolled thyrotoxicosis, the advantages of surgery in this setting become compelling. (See
         <a class="local">
          'Surgery'
         </a>
         above and
         <a class="local">
          'Surgery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the mechanism of the hyperthyroidism is uncertain or the patient appears to have "mixed" type I and type II AIT, a combination of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (40 mg/day) and
         <a class="drug drug_general" data-topicid="9627" href="/z/d/drug information/9627.html" rel="external">
          methimazole
         </a>
         (40 mg/day) is reasonable initial therapy. A rapid response suggests type II AIT; the methimazole can then be tapered or stopped. A poor or slow initial response argues for type I AIT. (See
         <a class="local">
          'Treatment if mechanism unknown'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med 2005; 118:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy RL, Griffiths H, Gray TA. Amiodarone and the thyroid. Clin Chem 1989; 35:1882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet 1984; 9:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martino E, Aghini-Lombardi F, Mariotti S, et al. Amiodarone: a common source of iodine-induced thyrotoxicosis. Horm Res 1987; 26:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao RH, McCready VR, Spathis GS. Iodine kinetic studies during amiodarone treatment. J Clin Endocrinol Metab 1986; 62:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franklyn JA, Davis JR, Gammage MD, et al. Amiodarone and thyroid hormone action. Clin Endocrinol (Oxf) 1985; 22:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Beeren HC, Bakker O, Wiersinga WM. Structure-function relationship of the inhibition of the 3,5,3'-triiodothyronine binding to the alpha1- and beta1-thyroid hormone receptor by amiodarone analogs. Endocrinology 1996; 137:2807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roti E, Minelli R, Gardini E, et al. Thyrotoxicosis followed by hypothyroidism in patients treated with amiodarone. A possible consequence of a destructive process in the thyroid. Arch Intern Med 1993; 153:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braverman LE, Ingbar SH, Vagenakis AG, et al. Enhanced susceptibility to iodide myxedema in patients with Hashimoto's disease. J Clin Endocrinol Metab 1971; 32:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stanbury JB, Ermans AE, Bourdoux P, et al. Iodine-induced hyperthyroidism: occurrence and epidemiology. Thyroid 1998; 8:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med 1997; 126:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991; 91:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997; 30:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Batcher EL, Tang XC, Singh BN, et al. Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. Am J Med 2007; 120:880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martino E, Safran M, Aghini-Lombardi F, et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 1984; 101:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsadok MA, Jackevicius CA, Rahme E, et al. Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations. CMAJ 2011; 183:E817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benjamens S, Dullaart RPF, Sluiter WJ, et al. The clinical value of regular thyroid function tests during amiodarone treatment. Eur J Endocrinol 2017; 177:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diederichsen SZ, Darkner S, Chen X, et al. Short-term amiodarone treatment for atrial fibrillation after catheter ablation induces a transient thyroid dysfunction: Results from the placebo-controlled, randomized AMIO-CAT trial. Eur J Intern Med 2016; 33:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fradkin JE, Wolff J. Iodide-induced thyrotoxicosis. Medicine (Baltimore) 1983; 62:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. N Engl J Med 1996; 335:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bagchi N, Brown TR, Urdanivia E, Sundick RS. Induction of autoimmune thyroiditis in chickens by dietary iodine. Science 1985; 230:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunn JT. Guarding our nation's thyroid health. J Clin Endocrinol Metab 2002; 87:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nademanee K, Singh BN, Callahan B, et al. Amiodarone, thyroid hormone indexes, and altered thyroid function: long-term serial effects in patients with cardiac arrhythmias. Am J Cardiol 1986; 58:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohammadi K, Shafie D, Vakhshoori M, et al. Prevalence of amiodarone-induced hypothyroidism; A systematic review and meta-analysis. Trends Cardiovasc Med 2023; 33:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martino E, Aghini-Lombardi F, Mariotti S, et al. Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases. Clin Endocrinol (Oxf) 1987; 26:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartalena L, Bogazzi F, Braverman LE, Martino E. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. J Endocrinol Invest 2001; 24:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nademanee K, Piwonka RW, Singh BN, Hershman JM. Amiodarone and thyroid function. Prog Cardiovasc Dis 1989; 31:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christidis G, Lammert F, Krawczyk M. Amiodarone and hypothyroidism. Lancet 2021; 397:704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartalena L, Brogioni S, Grasso L, et al. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol Metab 1996; 81:2930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev 2001; 22:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lambert M, Unger J, De Nayer P, et al. Amiodarone-induced thyrotoxicosis suggestive of thyroid damage. J Endocrinol Invest 1990; 13:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartalena L, Grasso L, Brogioni S, et al. Serum interleukin-6 in amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 1994; 78:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brennan MD, Erickson DZ, Carney JA, Bahn RS. Nongoitrous (type I) amiodarone-associated thyrotoxicosis: evidence of follicular disruption in vitro and in vivo. Thyroid 1995; 5:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouvy ML, Heerdink ER, Hoes AW, Leufkens HG. Amiodarone-induced thyroid dysfunction associated with cumulative dose. Pharmacoepidemiol Drug Saf 2002; 11:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogazzi F, Bartalena L, Dell'Unto E, et al. Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy. Clin Endocrinol (Oxf) 2007; 67:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yiu KH, Jim MH, Siu CW, et al. Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome. J Clin Endocrinol Metab 2009; 94:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Sullivan AJ, Lewis M, Diamond T. Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. Eur J Endocrinol 2006; 154:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomisti L, Rossi G, Bartalena L, et al. The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type. Eur J Endocrinol 2014; 171:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daniels GH. Amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 2001; 86:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martino E, Bartalena L, Mariotti S, et al. Radioactive iodine thyroid uptake in patients with amiodarone-iodine-induced thyroid dysfunction. Acta Endocrinol (Copenh) 1988; 119:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eaton SE, Euinton HA, Newman CM, et al. Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol (Oxf) 2002; 56:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogazzi F, Martino E, Dell'Unto E, et al. Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. J Endocrinol Invest 2003; 26:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piga M, Cocco MC, Serra A, et al. The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Eur J Endocrinol 2008; 159:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang J, Zhang R. Evaluation of 99mTc-MIBI in thyroid gland imaging for the diagnosis of amiodarone-induced thyrotoxicosis. Br J Radiol 2017; 90:20160836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cappellani D, De Marco G, Ferrarini E, et al. Identification of Two Different Phenotypes of Patients with Amiodarone-Induced Thyrotoxicosis and Positive Thyrotropin Receptor Antibody Tests. Thyroid 2021; 31:1463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogazzi F, Bartalena L, Tomisti L, et al. Continuation of amiodarone delays restoration of euthyroidism in patients with type 2 amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study. J Clin Endocrinol Metab 2011; 96:3374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eskes SA, Endert E, Fliers E, et al. Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial. J Clin Endocrinol Metab 2012; 97:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osman F, Franklyn JA, Sheppard MC, Gammage MD. Successful treatment of amiodarone-induced thyrotoxicosis. Circulation 2002; 105:1275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogazzi F, Bartalena L, Martino E. Approach to the patient with amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 2010; 95:2529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gershinsky M, Saliba W, Lavi I, et al. Increased Risk of Antithyroid Drug Agranulocytosis Associated with Amiodarone-Induced Thyrotoxicosis: A Population-Based Cohort Study. Thyroid 2019; 29:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martino E, Aghini-Lombardi F, Mariotti S, et al. Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole. J Endocrinol Invest 1986; 9:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickstein G, Shechner C, Adawi F, et al. Lithium treatment in amiodarone-induced thyrotoxicosis. Am J Med 1997; 102:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maqdasy S, Batisse-Lignier M, Auclair C, et al. Amiodarone-Induced Thyrotoxicosis Recurrence After Amiodarone Reintroduction. Am J Cardiol 2016; 117:1112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hermida JS, Jarry G, Tcheng E, et al. Radioiodine ablation of the thyroid to allow the reintroduction of amiodarone treatment in patients with a prior history of amiodarone-induced thyrotoxicosis. Am J Med 2004; 116:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartalena L, Bogazzi F, Chiovato L, et al. 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. Eur Thyroid J 2018; 7:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogazzi F, Miccoli P, Berti P, et al. Preparation with iopanoic acid rapidly controls thyrotoxicosis in patients with amiodarone-induced thyrotoxicosis before thyroidectomy. Surgery 2002; 132:1114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Houghton SG, Farley DR, Brennan MD, et al. Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience. World J Surg 2004; 28:1083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomisti L, Materazzi G, Bartalena L, et al. Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction. J Clin Endocrinol Metab 2012; 97:3515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cappellani D, Papini P, Pingitore A, et al. Comparison Between Total Thyroidectomy and Medical Therapy for Amiodarone-Induced Thyrotoxicosis. J Clin Endocrinol Metab 2020; 105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogazzi F, Tomisti L, Rossi G, et al. Glucocorticoids are preferable to thionamides as first-line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis: a matched retrospective cohort study. J Clin Endocrinol Metab 2009; 94:3757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uzan L, Guignat L, Meune C, et al. Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis. Drug Saf 2006; 29:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogazzi F, Bartalena L, Tomisti L, et al. Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations. J Clin Endocrinol Metab 2007; 92:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogazzi F, Bartalena L, Cosci C, et al. Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study. J Clin Endocrinol Metab 2003; 88:1999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yagishita A, Hachiya H, Kawabata M, et al. Amiodarone-induced thyrotoxicosis late after amiodarone withdrawal. Circ J 2013; 77:2898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurnik D, Loebstein R, Farfel Z, et al. Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland. Medicine (Baltimore) 2004; 83:107.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7834 Version 22.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15989900" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Amiodarone and the thyroid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2673586" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Amiodarone and the thyroid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6370540" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical pharmacokinetics of amiodarone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2885251" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Amiodarone: a common source of iodine-induced thyrotoxicosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3944239" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Iodine kinetic studies during amiodarone treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3978832" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Amiodarone and thyroid hormone action.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8770901" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Structure-function relationship of the inhibition of the 3,5,3'-triiodothyronine binding to the alpha1- and beta1-thyroid hormone receptor by amiodarone analogs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8466380" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Thyrotoxicosis followed by hypothyroidism in patients treated with amiodarone. A possible consequence of a destructive process in the thyroid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4926257" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Enhanced susceptibility to iodide myxedema in patients with Hashimoto's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9492158" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Iodine-induced hyperthyroidism: occurrence and epidemiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8992925" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Effects of amiodarone on thyroid function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1951413" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9283542" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Adverse effects of low dose amiodarone: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17904459" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6428291" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21746822" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28424174" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The clinical value of regular thyroid function tests during amiodarone treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27129624" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Short-term amiodarone treatment for atrial fibrillation after catheter ablation induces a transient thyroid dysfunction: Results from the placebo-controlled, randomized AMIO-CAT trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6218369" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Iodide-induced thyrotoxicosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8649497" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Chronic autoimmune thyroiditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4048936" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Induction of autoimmune thyroiditis in chickens by dietary iodine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11836273" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Guarding our nation's thyroid health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3776855" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Amiodarone, thyroid hormone indexes, and altered thyroid function: long-term serial effects in patients with cardiac arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35026394" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Prevalence of amiodarone-induced hypothyroidism; A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3665117" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11263469" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2652189" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Amiodarone and thyroid function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33610214" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Amiodarone and hypothyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8768854" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11294826" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The effects of amiodarone on the thyroid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2258582" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Amiodarone-induced thyrotoxicosis suggestive of thyroid damage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8106631" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Serum interleukin-6 in amiodarone-induced thyrotoxicosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7580265" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Nongoitrous (type I) amiodarone-associated thyrotoxicosis: evidence of follicular disruption in vitro and in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12462138" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Amiodarone-induced thyroid dysfunction associated with cumulative dose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17561980" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18940876" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16556715" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24935933" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11231968" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Amiodarone-induced thyrotoxicosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2845689" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Radioactive iodine thyroid uptake in patients with amiodarone-iodine-induced thyroid dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11849244" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14594114" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18603573" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28106465" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Evaluation of 99mTc-MIBI in thyroid gland imaging for the diagnosis of amiodarone-induced thyrotoxicosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34271828" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Identification of Two Different Phenotypes of Patients with Amiodarone-Induced Thyrotoxicosis and Positive Thyrotropin Receptor Antibody Tests.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21865355" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Continuation of amiodarone delays restoration of euthyroidism in patients with type 2 amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22130792" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11901034" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Successful treatment of amiodarone-induced thyrotoxicosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20525904" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Approach to the patient with amiodarone-induced thyrotoxicosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30648930" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Increased Risk of Antithyroid Drug Agranulocytosis Associated with Amiodarone-Induced Thyrotoxicosis: A Population-Based Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3020113" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9217642" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Lithium treatment in amiodarone-induced thyrotoxicosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26853955" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Amiodarone-Induced Thyrotoxicosis Recurrence After Amiodarone Reintroduction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14984821" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Radioiodine ablation of the thyroid to allow the reintroduction of amiodarone treatment in patients with a prior history of amiodarone-induced thyrotoxicosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29594056" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12490863" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Preparation with iopanoic acid rapidly controls thyrotoxicosis in patients with amiodarone-induced thyrotoxicosis before thyroidectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15490061" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22865896" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31545358" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Comparison Between Total Thyroidectomy and Medical Therapy for Amiodarone-Induced Thyrotoxicosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19622616" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Glucocorticoids are preferable to thionamides as first-line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis: a matched retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16524322" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17148557" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12727944" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24042320" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Amiodarone-induced thyrotoxicosis late after amiodarone withdrawal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15028964" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
